TY - JOUR
AU - Thys,, Jean-Pierre
AB - Abstract The role of the new fluoroquinolones in the treatment of lower respiratory tract infections is still difficult to assess. These compounds can be successfully used in the treatment of acuteexacerbations of chronic bronchitis but do not seem superior to older drugs; moreover, bacteriologic persistence and even treatment failures in infections due to Streptococcus pneumoniae can be a problem. Because of the poor activity of fluoroquinolones against S. pneumoniae, these compounds do not appear to be the first choice in the empiric treatment of community-acquired pneumonia. Ciprofloxacin is apparently valuable for the treatment of pseudomonas infections in patients withcystic fibrosis: clinical results seem comparable to those obtained with conventional intravenous treatments. More clinical experience is needed to compare the role of fluoroquinolones witht hat of β-1actam and aminoglycoside antibiotics in the treatmentof nosocomial gram-negative pneumonia. This content is only available as a PDF. © 1988 by The University of Chicago
TI - Quinolones in the Treatment of Bronchopulmonary Infections
JO - Clinical Infectious Diseases
DO - 10.1093/clinids/10.Supplement_1.S212
DA - 1988-01-01
UR - https://www.deepdyve.com/lp/oxford-university-press/quinolones-in-the-treatment-of-bronchopulmonary-infections-RqH0g948rb
SP - S212
EP - S217
VL - 10
IS - Supplement_1
DP - DeepDyve
ER -